Mindset and InterVivo Solutions Announce Availability of First Preclinical Psychedelic Benchmark Data from COPE Program Jun 14, 2021
Mindset Pharma Announces Positive Preclinical Results of Its Proprietary Next Generation DMT & 5-MeO-DMT Compounds Apr 29, 2021
Mindset Pharma Announces Strong Confirmation of In Vivo Proof-of-Concept Across Its Entire New Drug Program Portfolio Apr 20, 2021
Mindset Pharma Agrees to Manufacture Large Quantity of Pharmaceutical Grade Psilocybin Using Patent-Pending Synthesis… Feb 22, 2021